Withdrawn applications and products

COVID-19 vaccines withdrawn from marketing authorisation

Vaccine developers have withdrawn the marketing authorisation for the following COVID-19 vaccines:

2550100All entries per page

Search:

Vaccine	Vaccine developer	Key milestones	More information

Vaccine	Vaccine developer	Key milestones	More information
COVID-19 Vaccine (inactivated, adjuvanted) Valneva	Valneva Austria GmbH	Marketing authorisation issued: 24/06/2022   Withdrawal of the marketing authorisation: 12/10/2023	Public statement on COVID-19 Vaccine (inactivated, adjuvanted) Valneva
Jcovden (previously COVID-19 Vaccine Janssen)	Janssen-Cilag International NV	Conditional marketing authorisation issued: 11/03/2021 Annual renewal issued: 03/01/2022 Standard marketing authorisation issued: 10/01/2023 Withdrawal of the marketing authorisation: 09/08/2024	Public statement on Jcovden (COVID-19 Vaccine Janssen (Ad26.COV2.S)
Vaxzevria (previously COVID-19 Vaccine AstraZeneca)	AstraZeneca AB	Conditional marketing authorisation issued: 29/01/2021 Annual renewal issued: 09/11/2021 Standard marketing authorisation issued: 31/10/2022 Withdrawal of the marketing authorisation: 27/03/2024	Public statement on Vaxzevria (previously COVID-19 Vaccine AstraZeneca)
VidPrevtyn Beta	Sanofi Pasteur	Marketing authorisation issued: 10/11/2022 Withdrawal of the marketing authorisation: 11/03/2024	Public statement on VidPrevtyn Beta

Showing 1 to 4 of 4 entries

• «
• ‹
• 1
• ›
• »

COVID-19 vaccines withdrawn from rolling review

Vaccine developers have withdrawn the following COVID-19 vaccines from the rolling review process:

2550100All entries per page

Search:

Vaccine	Vaccine developer	Key milestones	More information

Vaccine	Vaccine developer	Key milestones	More information
CVnCoV	CureVac AG	Rolling review started: 12/02/2021   Withdrawn from rolling review: 12/10/2021	EMA ends rolling review of CVnCoV COVID-19 vaccine following withdrawal by CureVac AG Paediatric investigation plan

Showing 1 to 1 of 1 entry

• «
• ‹
• 1
• ›
• »

COVID-19 vaccines withdrawn from marketing authorisation evaluation

Vaccine developers have withdrawn the following COVID-19 vaccines from the marketing authorisation evaluation process:

2550100All entries per page

Search:

Vaccine	Vaccine developer	Key milestones	More information

Vaccine	Vaccine developer	Key milestones	More information
Skycovion	SK Chemicals GmbH	Marketing authorisation evaluation started: 18/08/2022   Withdrawn from marketing authorisation evaluation: 01/09/2023	Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 September 2023

Showing 1 to 1 of 1 entry

• «
• ‹
• 1
• ›
• »

COVID-19 treatments withdrawn from marketing authorisation evaluation

Treatment developers have withdrawn the following COVID-19 treatments from the marketing authorisation evaluation process:

2550100All entries per page

Search:

Treatment	Treatment developer	Key milestones	More information

Treatment	Treatment developer	Key milestones	More information
Lagevrio (molnupiravir)	Merck Sharp & Dohme and Ridgeback Biotherapeutics	Marketing authorisation evaluation started: 23/11/2021 CHMP negative opinion: 23/02/2023 Re-examination request submitted: 13/03/2023 Withdrawn from marketing authorisation evaluation: 21/06/2023
Olumiant (baricitinib)	Eli Lilly Nederland B.V.	Marketing authorisation evaluation started: 23/11/2021 Withdrawn from marketing authorisation evaluation: 07/12/2022	Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 December 2022

Showing 1 to 2 of 2 entries

• «
• ‹
• 1
• ›
• »

COVID-19 treatments withdrawn from rolling review

Treatment developers have withdrawn the following COVID-19 treatments from the rolling review process:

2550100All entries per page

Search:

Treatment	Treatment developer	Key milestones	More information

Treatment	Treatment developer	Key milestones	More information
Bamlanivimab and etesevimab	Eli Lilly	Rolling review started: 11/03/2021 Withdrawn from rolling review: 29/10/2021	Latest news Paediatric investigation plan for bamlanivimab Paediatric investigation plan for etesevimab

Showing 1 to 1 of 1 entry

• «
• ‹
• 1
• ›
• »